| 1. |
- Bui, Christine L, et al.
(författare)
-
Validation of acute liver injury cases in a population-based cohort study of oral antimicrobial users
- 2014
-
Ingår i: Current Drug Safety. - : Bentham Science Publishers Ltd.. - 1574-8863 .- 2212-3911. ; 9:1, s. 23-28
-
Tidskriftsartikel (refereegranskat)abstract
- We conducted a cohort study of acute, noninfectious liver injury among oral antimicrobial users. Potential cases were identified in the HealthCore Integrated Research Database (HIRD(SM)) population between July 1, 2001, and March 31, 2009, using ICD-9-CM codes primarily for acute and subacute necrosis of the liver, hepatic coma, and unspecified hepatitis.Liver test results were used to confirm case status according to published criteria. Two physician reviewers experienced in studying acute liver injury (blinded to study drug exposures) evaluated data abstracted from hospital and emergency department records to validate potential cases. Of 715 potential cases having claims associated with any of the primary screening codes, 312 (44%) were valid cases, 108 (15%) were not cases, and 295 (41%) were of uncertain status (records inadequate for validation). Among potential cases with adequate medical records, the PPV for presence of any of the primary codes was 74% (95% CI, 70%-78%). The highest PPV for a single code was for acute and subacute necrosis of the liver (84%; 95% CI, 77%-90%).Evaluation of cases of noninfectious liver injury using hospital and emergency department medical records continues to represent the preferred approach in studies using insurance claims data.
|
|
| 2. |
|
|
| 3. |
- Lövborg, Henrik, et al.
(författare)
-
A fatal outcome after unintentional overdosing of rivastigmine patches
- 2012
-
Ingår i: Current drug safety. - : Bentham Science Publishers Ltd.. - 2212-3911 .- 1574-8863. ; 7:1, s. 30-32
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Rivastigmine is an acetylcholine esterase inhibitor used in the treatment of dementia. Patches with rivastigmine for transdermal delivery have been used to increase compliance and to reduce side effects.CASE REPORT: We describe an 87-year old male with dementia treated with multiple rivastigmine patches (Exelon 9,5 mg/24 h) who developed nausea, vomiting and renal failure with disturbed electrolytes resulting in death. The symptoms occurred after six rivastigmine patches had concomitantly been erroneously applied by health care personnel on two consecutive days. The terminal cause of death was considered to be uremia from an acute tubular necrosis that was assessed as a result of dehydration through vomiting. The rivastigmine intoxication was assessed as having caused or contributed to the dehydrated condition. The medication error occurred at least partly due to ambiguous labeling. The clinical signs were not initially recognized as adverse effects of rivastigmine.DISCUSSION: The presented case is a description of a rivastigmine overdose due to a medication error involving patches. This case indicates the importance of clear and unambiguous instructions to avoid administration errors with patches and to be vigilant to adverse drug reactions for early detection and correction of drug administration errors. In particular, instructions clearly indicating that only one patch should be applied at a time are important.
|
|
| 4. |
- Mosekilde, L, et al.
(författare)
-
Emerging anabolic treatments in osteoporosis
- 2011
-
Ingår i: Current drug safety. - : Bentham Science Publishers Ltd.. - 2212-3911 .- 1574-8863. ; 6:2, s. 62-74
-
Tidskriftsartikel (refereegranskat)
|
|
| 5. |
|
|
